AbbVie Inc. (NYSE:ABBV) on Thursday released topline results from the second of two pivotal studies of the Phase 3 UP-AA clinical program evaluating the safety and efficacy of upadacitinib (RINVOQ; 15 mg and 30 mg, once daily) in adult and adolescent patients with severe alopecia areata (AA) with a mean baseline SALT score of 84.0 (approximately 16% scalp hair coverage).
Alopecia areata is an autoimmune disease causing hair loss, typically in small, round patches on the scalp or other body areas. It occurs when the immune system mistakenly attacks hair follicles.
